HME Business

  • Home
  • Topics
    • COVID-19
    • Accreditation
    • Competitive Bidding
    • DME Pharmacy
    • Legislative
    • Mobility
    • Oxygen
    • Pain Management
    • Retail
    • Sales and Marketing
    • Sleep Therapy
    • Software/IT
  • News
  • Resources
    • Whitepapers
    • Buyers Guide
    • DME Associations
  • Podcasts
  • Request Media Kit
  • Webinars
  • Digital Edition
  • Events
  • Awards
  • Advertise
  • Subscribe

Tiotropium Reduces Exacerbations and Associated Health Resource Use in Patients with COPD

March 1, 2006 by HME Business

PARIS &#151 New data from a large one-year study published in the March issue of the European Respiratory Journal show that tiotropium significantly reduces exacerbations and associated health resource use in patients with COPD compared with placebo. Tiotropium is an anticholinergic medication recommended for maintenance treatment of patients with COPD.


COPD, a progressive respiratory illness that causes significant deterioration of lung function and chronic breathlessness, affects 600 million people worldwide, but its prevalence is predicted to rise to become the world’s third leading cause of death by 2020.


“These study results are very good news for both patients and their health care providers,” said Professor Dusser, head of Pneumology, Hopital Cochin, and principal study investigator. “Treatments for COPD that can reduce the frequency or severity of exacerbations and associated health resource use can have a significant impact on both patients’ quality of life and the cost of treatment. This study has shown that, with tiotropium, we have an effective treatment option to achieve this.”


The study was a one-year randomized, double-blind, parallel group study involving 1,010 patients from 177 centers in France. Compared with placebo, treatment with tiotropium:


  • significantly delayed the time to first exacerbation by approximately 100 days

  • reduced the proportion of patients experiencing more that one exacerbation by 17 percent

  • decreased the number of exacerbations by 35 percent and exacerbation days by 37 percent

  • decreased health resource use, including a reduction in the number of unscheduled physician visits by 41 percent and phone calls to a physician by 53 percent and also a reduction in concomitant respiratory medications, antibiotics and oral steroids.


Treatment also significantly improved airflow in patients over one year compared with placebo, as measured by a significant improvement in (trough) pre-dose FEV1 (forced expiratory volume in one second).


Source: Hospital Cochin

Related Articles Read More >

HME Business Survey: Call for Participants on Revenue Cycle & Operational Technology
Home medical equipment professionals are eligible to take the new survey.
Sumitomo Corp. Acquires ActivStyle LLC in Latest HME Investment
Last month, Sumitomo announced it had increased its stake in Vast Medical Holdings, parent company of HME provider Quest.
May 2025: How Science Is Backing HME
New research is demonstrating the clinical and financial value of home medical equipment.
ASPEN, WCCC Launch Industry Surveys
Featuring the American Society for Parenteral and Enteral Nutrition and the Wound Care Collaborative Community.

Get the free newsletter

Home Healthcare Softare

Subscribe to HME Business for industry & product news, trends and resources.
HME Business Directory
HME Podcasts
continuum event
HME Business
  • Mobility Management
  • Senior Housing News
  • Home Health Care News
  • Skilled Nursing News
  • Hospice News
  • Behavioral Health Business
  • About HME Business
  • Contact Us

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search HME Business

  • Home
  • Topics
    • COVID-19
    • Accreditation
    • Competitive Bidding
    • DME Pharmacy
    • Legislative
    • Mobility
    • Oxygen
    • Pain Management
    • Retail
    • Sales and Marketing
    • Sleep Therapy
    • Software/IT
  • News
  • Resources
    • Whitepapers
    • Buyers Guide
    • DME Associations
  • Podcasts
  • Request Media Kit
  • Webinars
  • Digital Edition
  • Events
  • Awards
  • Advertise
  • Subscribe